---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-273688"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:14:42.579459+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyell reports 94% ORR, 71% CR for IMPT-314 in Phase 1-2 large B-cell lymphoma trial

## Summary
- Objective response rate 94% (16/17) and complete response rate 71% (12/17) in CAR T-naive patients with ≥2 prior therapies.
- No Grade 3+ cytokine release syndrome; Grade 3 ICANS in 13% (3/23) with median resolution time of 5 days.
- Median follow-up 6.3 months; 71% of patients remained in response at last follow-up.
- Plans to initiate a pivotal trial in 2025 for 3rd-line+ large B-cell lymphoma and continues 2nd-line evaluation.
- Final product enriched for naïve/central memory T cells (median 91%), linked to improved overall survival in other studies.

## SEC filing metadata
- accession: 0001193125-24-273688
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312524273688/0001193125-24-273688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312524273688/d873794d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-273688
- JSON: https://secwatch.observer/filing/0001193125-24-273688.json
- Plain text: https://secwatch.observer/filing/0001193125-24-273688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.